INmune Bio Inc (INMB)
11.21
-0.36
(-3.11%)
USD |
NASDAQ |
May 06, 16:00
11.21
0.00 (0.00%)
After-Hours: 20:00
INmune Bio Shareholders Equity (Quarterly): 38.14M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 38.14M |
| September 30, 2023 | 44.73M |
| June 30, 2023 | 50.65M |
| March 31, 2023 | 55.30M |
| December 31, 2022 | 60.10M |
| September 30, 2022 | 63.71M |
| June 30, 2022 | 69.93M |
| March 31, 2022 | 75.64M |
| December 31, 2021 | 80.22M |
| September 30, 2021 | 88.26M |
| June 30, 2021 | 43.23M |
| March 31, 2021 | 63.56M |
| Date | Value |
|---|---|
| December 31, 2020 | 38.75M |
| September 30, 2020 | 41.21M |
| June 30, 2020 | 21.68M |
| March 31, 2020 | 22.41M |
| December 31, 2019 | 23.61M |
| September 30, 2019 | 24.71M |
| June 30, 2019 | 26.84M |
| March 31, 2019 | 22.86M |
| December 31, 2018 | 16.54M |
| September 30, 2018 | 17.47M |
| December 31, 2017 | 18.10M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
21.68M
Minimum
Jun 2020
88.26M
Maximum
Sep 2021
49.09M
Average
44.73M
Median
Sep 2023
Shareholders Equity (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 5.074B |
| Sarepta Therapeutics Inc | 961.19M |
| Dare Bioscience Inc | -5.048M |
| Zevra Therapeutics Inc | 61.86M |
| Kodiak Sciences Inc | 265.78M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 57.00M |
| Total Liabilities (Quarterly) | 18.86M |
| Debt to Equity Ratio | 0.2601 |
| Current Ratio | 2.163 |
| Net Debt Paydown Yield | 0.47% |